KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBIT Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBIT Margin data on record, last reported at 22.65% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 945313.0% year-over-year to 22.65%; the TTM value through Dec 2025 reached 24.95%, down 3339.0%, while the annual FY2025 figure was 24.95%, 315.0% down from the prior year.
  • EBIT Margin reached 22.65% in Q4 2025 per REGN's latest filing, down from 27.35% in the prior quarter.
  • Across five years, EBIT Margin topped out at 46488.89% in Q2 2021 and bottomed at 9430.48% in Q4 2024.
  • Average EBIT Margin over 5 years is 1405.75%, with a median of 28.36% recorded in 2025.
  • Peak YoY movement for EBIT Margin: surged 4645526bps in 2021, then tumbled -4426909bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 21.74% in 2021, then soared by 5174bps to 1146.8% in 2022, then plummeted by -564bps to 5316.39% in 2023, then tumbled by -77bps to 9430.48% in 2024, then skyrocketed by 100bps to 22.65% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 22.65% in Q4 2025, 27.35% in Q3 2025, and 29.37% in Q2 2025.